Patents by Inventor Yajing Liu
Yajing Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250055731Abstract: A communication method includes generating a first sequence, where the first sequence is based on a complete complementary code set, the complete complementary code set is based on a Golay pair and a Hadamard matrix through a Kronecker product operation, and the first sequence is used for channel estimation; and sending the first sequence. In the method, use of a P-matrix is avoided in a process of constructing a plurality of streams of zero correlation sequences.Type: ApplicationFiled: October 18, 2024Publication date: February 13, 2025Inventors: Zhengchun Zhou, Rui Du, Yajing Zhou, Xiaohu Tang, Chenchen Liu, Xiao Han
-
Patent number: 12203077Abstract: Provided are base editors containing a cytidine and a catalytically inactive version of Lachnospiraceae bacterium Cpf1 (LbCpf1). The new base editors have greatly improved editing efficiency and fidelity as compared to Cas9-based base editors, and have different editing windows.Type: GrantFiled: August 28, 2018Date of Patent: January 21, 2025Assignee: ShanghaiTech UniversityInventors: Jia Chen, Xingxu Huang, Li Yang, Bei Yang, Xiaosa Li, Ying Wang, Yajing Liu
-
Patent number: 12196753Abstract: A kit for detecting drug-resistant tuberculosis, includes: detection reagents, configured to perform quantitative detection on 17 serum metabolites of patients with tuberculosis, the 17 serum metabolites comprising: taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-tetrachlorophthalic anhydride, malotilate, fulvic acid, and L-neopterin.Type: GrantFiled: May 11, 2024Date of Patent: January 14, 2025Assignee: Zhejiang SUKEAN Pharmaceutical Co., Ltd.Inventors: Pintong Huang, Yajing Liu, Yan Su, Chao Zhang
-
Patent number: 12134771Abstract: A fusion protein which may comprise a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment for cytosine deamination at the target site. The fusion protein may comprise a first nCas9 fragment, a chimeric insertion fragment and a second nCas9 fragment from N-terminus to C-terminus, wherein the chimeric insertion fragment is TadA-TadA* for cytosine deamination at the target site. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.Type: GrantFiled: January 5, 2023Date of Patent: November 5, 2024Assignee: ShanghaiTech UniversityInventors: Yajing Liu, Shisheng Huang, Xingxu Huang
-
Patent number: 12123006Abstract: The present disclosure relates to the field of biotechnology, in particular to a base editing tool and use thereof. The present disclosure provides a fusion protein comprising a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce of off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.Type: GrantFiled: May 18, 2021Date of Patent: October 22, 2024Assignee: SHANGHAITECH UNIVERSITYInventors: Yajing Liu, Shisheng Huang, Xingxu Huang
-
Publication number: 20240295555Abstract: A kit for detecting drug-resistant tuberculosis, includes: detection reagents, configured to perform quantitative detection on 17 serum metabolites of patients with tuberculosis, the 17 serum metabolites comprising: taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-tetrachlorophthalic anhydride, malotilate, fulvic acid, and L-neopterin.Type: ApplicationFiled: May 11, 2024Publication date: September 5, 2024Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
-
Publication number: 20240295569Abstract: A tuberculosis detection kit includes diagnostic reagents for 17 serum metabolites of patients with tuberculosis, the detecting reagent being used for quantitative detection of the 17 serum metabolites of the patients with tuberculosis, the 17 serum metabolites comprising D-Leucic acid, Leucinic acid, L-Cystine, MG(0:0/14:0/0:0), S-Lactoylglutathione, Octacosanoic acid, Cer(d18:1/12:0), Raffinose, LysoPC(20:1(11Z)/0:0), LysoPC(22:4(7Z,10Z,13Z,16Z)/0:0), PC(18:1(9Z)e/2:0), Torvoside G(TG(15:0/15:0/15:0)), CE(16:1(9Z)), all-trans-Heptaprenyl diphosphate, PC(15:0/16:0), NADP, TG(20:0/20:0/20:1(11Z)).Type: ApplicationFiled: May 11, 2024Publication date: September 5, 2024Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
-
Publication number: 20240191339Abstract: Provided are a nanocomposite dielectric film material for energy storage prepared by vertical self-assembly of lead zirconate titanate (PZT) and magnesium oxide (MgO), and a preparation method thereof. The method includes: 1, preparing a PZT powder; 2, mixing the PZT powder with an MgO powder to obtain a uniformly mixed PM composite powder; and mixing the PM composite powder with a binder, and subjecting a resulting mixture to tableting and cold isostatic pressing to obtain a PM composite target blank; 3, sintering the PM composite target blank at a temperature of not higher than 900° C. to obtain a PM composite target; and 4, subjecting the PM composite target to pulsed laser deposition to form an epitaxial vertical self-assembly composite dielectric film; and subjecting the epitaxial vertical self-assembly composite dielectric film to annealing to obtain the film material.Type: ApplicationFiled: November 28, 2023Publication date: June 13, 2024Inventors: Weiwei Li, Yajing Liu
-
Publication number: 20230358766Abstract: A set of serum metabolic biomarkers and detection kit for detecting tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers comprising D-Leucic acid, Leucinic acid, L-Cystine, MG(0:0/14:0/0:0), S-Lactoylglutathione, Octacosanoic acid, Cer(d18:1/12:0), Raffinose, LysoPC(20:1(11Z)/0:0), LysoPC(22:4(7Z,10Z,13Z,16Z)/0:0), PC(18:1(9Z)e/2:0), Torvoside G(TG(15:0/15:0/15:0)), CE(16:1(9Z)), all-trans-Heptaprenyl diphosphate, PC(15:0/16:0), NADP, TG(20:0/20:0/20:1(11Z)). The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The tuberculosis detection model based on the levels of the 17 metabolic biomarkers can achieve an area under the ROC curve of 99.5%, sensitivity of 98.2%, and specificity of 95.8% in detecting tuberculosis.Type: ApplicationFiled: July 12, 2023Publication date: November 9, 2023Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
-
Publication number: 20230349900Abstract: A set of serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis are provided. The set of the serum metabolic biomarkers includes 17 serum metabolic biomarkers. The 17 serum metabolic biomarkers are verified to be associated with tuberculosis based on the level changes of these biomarkers. The 17 metabolites includes taurine, homocysteine, uric acid, ascorbic acid, suberylglycine, uridine, dopamine 4-sulfate, inosinic acid, glyceraldehyde phosphate, [3-methoxy-4-(phosphoryl)phenyl]carbonyl sulfonic acid, nuclomedone, n4-cyclopropyl-6-(2,3-dichlorophenyl)-1,2,3,4-tetrahydropyrimidine-2,4-diimine, 1-[2-chlorine-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole, tetrachloro-phthalic anhydride, malotilate, fulvic acid, and L-neopterin. The serum metabolic biomarkers and detection kit for detecting drug-resistant tuberculosis can assist doctors in accurately diagnosing the disease, which is of great significance for the diagnosis and mass screening for drug-resistant tuberculosis.Type: ApplicationFiled: July 12, 2023Publication date: November 2, 2023Applicant: Zhejiang SUKEAN Pharmaceutical Co., Ltd.Inventors: Pintong HUANG, Yajing LIU, Yan SU, Chao ZHANG
-
Publication number: 20230313205Abstract: A fusion protein which may comprise a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment for cytosine deamination at the target site. The fusion protein may comprise a first nCas9 fragment, a chimeric insertion fragment and a second nCas9 fragment from N-terminus to C-terminus, wherein the chimeric insertion fragment is TadA-TadA* for cytosine deamination at the target site. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.Type: ApplicationFiled: January 5, 2023Publication date: October 5, 2023Applicant: ShanghaiTech UniversityInventors: Yajing LIU, Shisheng HUANG, Xingxu HUANG
-
Publication number: 20230219911Abstract: A compound represented by general formula (I) or stereoisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method therefor and a pharmaceutical composition containing the compound. An application of the compound of general formula (I) in preparation of drugs for treating and/or preventing she-mediated diseases, especially an application in preparation of drugs for treating inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes, diabetes complications, diabetes-related diseases, fibrotic diseases, neurological and mental diseases, pain, and ulcer diseases, etc.Type: ApplicationFiled: June 1, 2021Publication date: July 13, 2023Inventors: Yanfang ZHAO, Zibin GAO, Yufei HAN, Shuo LI, Yunlei HOU, Huimin ZHANG, Sicong XU, Yanping SUN, Mingze QIN, Yongjun SUN, Yajing LIU, Ping GONG
-
Publication number: 20220372497Abstract: The present disclosure relates to the field of biotechnology, in particular to a base editing tool and use thereof. The present disclosure provides a fusion protein comprising a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce of off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.Type: ApplicationFiled: May 18, 2021Publication date: November 24, 2022Inventors: Yajing LIU, Shisheng HUANG, Xingxu HUANG
-
Patent number: 11481041Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.Type: GrantFiled: July 22, 2020Date of Patent: October 25, 2022Assignee: Microsoft Technology Licensing, LLCInventors: Michael Francis Deily, Michael Gordon Oldani, Yajing Liu, David Paul Platt, David Michael Lane, Thomas Joseph Longo
-
Publication number: 20220259196Abstract: The present invention relates to a 2-aminopyrimidine compound shown in formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof, preparation methods for the 2-aminopyrimidine compound, and the pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutical composition comprising the compound. Substituents R1, R2, R3, R4, X, Y, Z, Q, m, and n have meanings given in the description. The present invention further relates to the application of the compound of formula I in the preparation of a medication for treating and/or preventing a malignant hematologic disease and other proliferative diseases.Type: ApplicationFiled: July 1, 2020Publication date: August 18, 2022Applicant: Shenyang Pharmaceutical UniversityInventors: Yanfang Zhao, Yingxiu Li, Mingze Qin, Yunlei Hou, Yajing Liu, Ping Gong
-
Publication number: 20220249771Abstract: Methods and systems for estimating force and motor torque in a mechatronic system are provided herein. Such methods and system are suited for improved control of small-scale mechatronic system, particularly a syringe, valve, and cartridge loader or door opening/closing mechanism of a diagnostic assay system. The methods can compensate for friction and account for various second-order effects, thereby allowing for more accurate pressure estimation, thereby allowing improved syringe operation. The methods can further allow for improved estimation of force or motor torque to allow for improved control of an actuatable valve interfacing the sample cartridge and cartridge loader or door opening/closing system. Methods of calibrating such systems are also provided.Type: ApplicationFiled: January 13, 2022Publication date: August 11, 2022Inventors: Rajesh Nerkar, Amrita Chimni, Yajing Liu, Janaki-rama Vegiraju, Ricahard J. Casler
-
Patent number: 11144092Abstract: Aspects of the present disclosure include connection mechanisms for a peripheral computing device to connect with a mobile computing device. The peripheral computing device may include a device interface component that defines part of the connection mechanisms, and an electrical connection protrusion extending from the device interface component and configured to insert in a corresponding electrical receptacle of a computing device. The device interface component may also include a magnetically connectable docking member configured to magnetically attract or to be magnetically attracted to a corresponding docking component on the computing device. The device interface component may further include a support rail configured to support the electrical connection protrusion and the magnetically connectable docking member. The support rail may comprise a shoulder configured to define a pivot point to guide connecting the peripheral computing device with the computing device.Type: GrantFiled: June 28, 2019Date of Patent: October 12, 2021Assignee: Microsoft Technology Licensing, LLCInventors: Anthony James Hewett, Katherine Margaret Bailey, Ketan R. Shah, Yajing Liu, Karsten Aagaard, Scott Jeffrey Korn, Christopher Alan Schafer, Cesar Ambriz Rios, Alex Sai Cheong Cheng
-
Publication number: 20200409414Abstract: Aspects of the present disclosure include connection mechanisms for a peripheral computing device to connect with a mobile computing device. The peripheral computing device may include a device interface component that defines part of the connection mechanisms, and an electrical connection protrusion extending from the device interface component and configured to insert in a corresponding electrical receptacle of a computing device. The device interface component may also include a magnetically connectable docking member configured to magnetically attract or to be magnetically attracted to a corresponding docking component on the computing device. The device interface component may further include a support rail configured to support the electrical connection protrusion and the magnetically connectable docking member. The support rail may comprise a shoulder configured to define a pivot point to guide connecting the peripheral computing device with the computing device.Type: ApplicationFiled: June 28, 2019Publication date: December 31, 2020Inventors: Anthony James Hewett, Katherine Margaret Bailey, Ketan R. Shah, Yajing Liu, Karsten Aagaard, Scott Jeffrey Korn, Christopher Alan Schafer, Cesar Ambriz Rios, Alex Sai Cheong Cheng
-
Publication number: 20200354729Abstract: Provided are base editors containing a cytidine and a catalytically inactive version of Lachnospiraceae bacterium Cpf1 (LbCpf1). The new base editors have greatly improved editing efficiency and fidelity as compared to Cas9-based base editors, and have different editing windows.Type: ApplicationFiled: August 28, 2018Publication date: November 12, 2020Inventors: Jia Chen, Xingxu Huang, Li Yang, Bei Yang, Xiaosa Li, Ying Wang, Yajing Liu
-
Publication number: 20200348762Abstract: Low-profile keysets and input devices having such low-profile keysets are described. In one example, the input device includes a support structure having a first and second surface; a bezel having a first and second surface, wherein the first surface of the bezel is adjacent to the first surface of the support structure, and the bezel comprises at least one opening; at least one key cap positioned within the at least one opening of the bezel, wherein each key cap is configured to move between a first and second position to trigger a function of the input device; and a fabric cover layer positioned adjacent to the second surface of the bezel, such that the bezel and the at least one key cap are positioned between the fabric cover layer and the support structure, the fabric cover layer is only adhered to the second surface of the bezel.Type: ApplicationFiled: July 22, 2020Publication date: November 5, 2020Inventors: Michael Francis DEILY, Michael Gordon OLDANI, Yajing LIU, David Paul PLATT, David Michael LANE, Thomas Joseph LONGO